ID-100214253The FDA just approved Cosentyx, a new biologic drug made by Novartis to treat adults with a moderate to severe plaque psoriasis. Psoriasis is caused by dysfunction of the immune system and plaque psoriasis associated with the development of thick, red skin with flaky, silver-white patches called scales is the most common form of the disease. Cosentyx is an injectable drug that targets the inflammation-causing protein interleukin-17 (IL-17). Novartis will not be the only company to produce IL-17 inhibitors in 2015. What are your thoughts about this new type of biologic used to treat plaque psoriasis? How does this class compare to the current therapy with tumor necrosis factor blockers?

For additional information click here

Photo courtesy of [stockimages]